Proteomic Analysis of Human Lung Development
Charles Ansong1, Gloria Pryhuber2, Geremy Clair1*
1Pacific Northwest National Laboratory, 2University of Rochester Medical Center, *Corresponding author
Rationale: The current understanding of human lung development derives mostly from animal studies. Although transcript-level studies have analyzed human donor tissue to identify genes expressed during normal human lung development, protein-level analysis that would enable the generation of new hypotheses on the processes involved in pulmonary development are lacking. Objectives: To define the temporal dynamic of protein expression during human lung development. Methods: We performed proteomics analysis of human lungs at 10 distinct times from birth to 8 years to identify the molecular networks mediating postnatal lung maturation. Measurements and Main Results: We identified 8,938 proteins providing a comprehensive view of the developing human lung proteome. The analysis of the data supports the existence of distinct molecular substages of alveolar development and predicted the age of independent human lung samples, and extensive remodeling of the lung proteome occurred during postnatal development. Evidence of post-transcriptional control was identified in early postnatal development. An extensive extracellular matrix remodeling was supported by changes in the proteome during alveologenesis. The concept of maturation of the immune system as an inherent part of normal lung development was substantiated by flow cytometry and transcriptomics. Conclusions: This study provides the first in-depth characterization of the human lung proteome during development, providing a unique proteomic resource freely accessible at The data support the extensive remodeling of the lung proteome during development, the existence of molecular substages of alveologenesis, and evidence of post-transcriptional control in early postnatal development.
LungMAP ID: LMEX0000004395
Organism: human
Stages: neonate | infant | child
Assay type: Proteomics
LungMAP IDAlt IDSpeciesSexRaceAgeAge GroupGA at BirthCGAWeightWeight PercentileCause of DeathType of DeathHealth Status
LMSP0000000128D004Homo sapiensMaleWhite5 daysNeonate41 weeks, 0 days41.86 weeks3.63 kg61Anoxic/Hypoxic Brain InjuryDBD (after brain death)No known lung disease
LMSP0000000129D005Homo sapiensMaleWhite1 dayNeonate39 weeks, 6 days39.86 weeks2.87 kg17Congenital AnomalyDCD (circulatory death)No known lung disease
LMSP0000000034D007Homo sapiensMaleAfrican American4 yearsChild15.42 kg17TraumaDBD (after brain death)No known lung disease
LMSP0000000135D012Homo sapiensMaleWhite2 yearsChild19.5 kg100Anoxic/Hypoxic Brain InjuryDBD (after brain death)No known lung disease
LMSP0000000142D019Homo sapiensMaleWhite1 dayNeonate37 weeks, 3 days37.43 weeks kg0Congenital AnomalyDCD (circulatory death)No known lung disease
LMSP0000000143D020Homo sapiensMaleOther24 daysNeonate41 weeks, 1 days44.57 weeks4.08 kg39Anoxic/Hypoxic Brain InjuryDBD (after brain death)No known lung disease
LMSP0000000035D024Homo sapiensMaleOther4 monthsInfant8.62 kg94TraumaDBD (after brain death)No known lung disease
LMSP0000000152D031Homo sapiensMaleWhite7 monthsInfant7.26 kg8.2Anoxic/Hypoxic Brain InjuryDBD (after brain death)No known lung disease
LMSP0000000157D036Homo sapiensMaleWhite8 yearsChild34 kg89TraumaDBD (after brain death)No known lung disease
LMSP0000000168D047Homo sapiensMaleWhite12 daysNeonate36 weeks, 0 days37.71 weeks3.3 kg67OtherDBD (after brain death)No known lung disease
LMSP0000000173D052Homo sapiensMaleAfrican American13 monthsChild9.5 kg32TraumaDBD (after brain death)No known lung disease
File Description Size
Clair et al. (2022) Supplement 29.1 MB